In today’s, society multi-resistant pathogens have become an emerging threat, which makes the search for novel anti-infectives more urgent than ever. A promising class of substances are cyclic lipopeptides like the antifungal jagaricin. Jagaricin is formed by the bacterial mushroom pathogen Janthinobacterium agaricidamnosum. It has shown antifungal activity against human pathogenic fungi like Candida albicans and Aspergillus fumigatus. In addition, jagaricin is nearly non-toxic for plants, which makes it a promising agent for agricultural applications. Cyclic lipopeptides formed by microorganisms originate from their secondary metabolism. This makes it very challenging to determine the inducing factor for product formation, especially for unknown microbial systems like J. agaricidamnosum. In the presented study, a biotechnological process for jagaricin formation was developed, investigating impact factors like the medium, oxygen availability, and phosphate. For this reason, experiments were conducted on microtiter plate, shake flask, and stirred tank bioreactor level. Ultimately, a final maximum jagaricin concentration of 251 mg L⁻¹ (15.5 mg_Jagaricin∙g_CDW⁻¹) could be achieved, which is an increase of approximately 458 % in comparison to previous results in standard glucose medium. This concentration allows the production of significantly higher amounts of jagaricin and enables further experiments to investigate the potential of this substance.

在当今社会，多重耐药病原体已成为一种新兴威胁，这使得寻找新型抗感染药物比以往任何时候都更加紧迫。一类有前途的物质是环状脂肽，如抗真菌药物 Jagaricin。Jagaricin 由细菌蘑菇病原体Janthinobacterium agaricidamnosum 形成。它对人类致病真菌如白色念珠菌和烟曲霉显示出抗真菌活性. 此外，jagaricin 对植物几乎无毒，这使其成为一种很有前景的农业应用剂。微生物形成的环状脂肽来源于它们的二次代谢。这使得确定产物形成的诱导因素变得非常具有挑战性，特别是对于像J. agaricidamnosum这样的未知微生物系统。在本研究中，开发了一种用于形成jagaricin 的生物技术过程，研究了培养基、氧气可用性和磷酸盐等影响因素。出于这个原因，在微量滴定板、摇瓶和搅拌罐生物反应器水平上进行了实验。最终，251 mg L ^-1的最终最大 Jagaricin 浓度（15.5 mg _Jagaricin ∙g _CDW ^-1) 可以实现，与以前在标准葡萄糖培养基中的结果相比，增加了大约 458%。这种浓度可以产生显着更高量的jagaricin，并使进一步的实验能够研究这种物质的潜力。